Download PDF
Synlett 2023; 34(16): 1905-1910
DOI: 10.1055/s-0041-1738446
letter

Synthesis and Cytotoxicity Evaluation of Tyrosine-5 Fluorinated Analogues of RA-VII, An Antitumor Bicyclic Hexapeptide

Yuki Yoshida
,
Chihiro Nagaishi
,
Tomoyo Hasuda
,
Hyun-Sun Park
,
Koichi Takeya
,
Yukio Hitotsuyanagi  ∗
This work was supported by JSPS KAKENHI Grants 24590024 and 19K07141.
› Further Information
    Permissions and Reprints All articles of this category


Abstract

RA-VII analogues fluorinated at each ε-position of Tyr-5 were designed. The synthesis of these peptide analogues commenced with the preparation of atropisomeric fluorocycloisodityrosines from protected 3-fluoro-L-tyrosyl-3-boronyl-L-tyrosine mediated by copper(II) acetate and 4-(dimethylamino)pyridine. After N-methylation, the tetrapeptide segment was coupled with the N-terminus of each fluorocycloisodityrosine to afford a hexapeptide. After removal of the C- and N-terminal protecting groups, each peptide was subjected to macrocyclization to produce an analogue. The analogue with a β-oriented fluorine atom was equipotent to RA-VII with regard to cytotoxicity toward human mammary carcinoma MCF-7 cells, and showed 2.1-fold and 1.4-fold lower cytotoxicities than RA-VII toward human promyelocytic leukemia HL-60 and human colorectal cancer HCT-116 cells, respectively, whereas the analogue with an α-oriented fluorine atom showed 7.7-fold, 6.0-fold, and 14-fold lower cytotoxicities than RA-VII toward those cells, respectively.

Key words

RA-VII analogues - peptides - macrocyclic peptides - medicinal chemistry - cytotoxicity - Rubia cordifolia

Supporting Information

    Supporting information for this article is available online at https://doi.org/10.1055/s-0041-1738446.
  • Supporting Information


Publication History

Received: 30 April 2023

Accepted after revision: 24 May 2023

Article published online:
10 July 2023

© 2023. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References and Notes

  • 1 Itokawa H, Takeya K, Mihara K, Mori N, Hamanaka T, Sonobe T, Iitaka Y. Chem. Pharm. Bull. 1983; 31: 1424
    CrossrefPubMed
  • 2 Itokawa H, Takeya K, Hitotsuyanagi Y, Morita H. In The Alkaloids, Vol. 49. Cordell GA. Academic Press; New York: 1997: 301
    Google Scholar
  • 3 Jolad SD, Hoffman JJ, Torrance SJ, Wiedhopf RM, Cole JR, Arora SK, Bates RB, Gargiulo RL, Kriek GR. J. Am. Chem. Soc. 1977; 99: 8040
    CrossrefPubMed
    • 4a Majima H, Tsukagoshi S, Furue H, Suminaga M, Sakamoto K, Wakabayashi R, Kishino S, Niitani H, Murata A, Genma A, Nukariya N, Uematsu K, Furuta T, Kurihara M, Yoshida F, Isomura S, Takemoto T, Hirashima M, Izumi T, Nakao I, Ohashi Y, Ito K, Asai R. Gan to Kagaku Ryoho 1993; 20: 67
      PubMed
    • 4b Yoshida F, Asai R, Majima H, Tsukagoshi S, Furue H, Suminaga M, Sakamoto K, Niitani H, Murata A, Kurihara M, Izumi T, Nakao I, Ohashi Y, Ito K. Gan to Kagaku Ryoho 1994; 21: 199
      PubMed
  • 5 Zalacaín M, Zaera E, Vázquez D, Jiménez A. FEBS Lett. 1982; 148: 95
    CrossrefPubMed
  • 6 Sirdeshpande BV, Toogood PL. Bioorg. Chem. 1995; 23: 460
    CrossrefPubMed
  • 7 Miyoshi T, Nomura T, Takeya K, Uchiumi T. Biochem. Biophys. Res. Commun. 2022; 615: 88
    CrossrefPubMed
  • 8 Fujiwara H, Saito S, Hitotsuyanagi Y, Takeya K, Ohizumi Y. Cancer Lett. 2004; 209: 223
    CrossrefPubMed
  • 9 Hitotsuyanagi Y, Odagiri M, Kato S, Kusano J, Hasuda T, Fukaya H, Takeya K. Chem. Eur. J. 2012; 18: 2839
    CrossrefPubMed
  • 10 Itokawa H, Kondo K, Hitotsuyanagi Y, Nakamura A, Morita H, Takeya K. Chem. Pharm. Bull. 1993; 41: 1266
    CrossrefPubMed
  • 11 Lee S, Ito I, Kondo K, Takeya K, Yamagishi T, Nagate T, Itokawa H. J. Chem. Soc., Perkin Trans. 1 1996; 213
    CrossrefPubMed
  • 12 Hitotsuyanagi Y, Lee J.-E, Kato S, Kim I.-H, Kohashi H, Fukaya H, Takeya K. Bioorg. Med. Chem. 2011; 19: 2458
    CrossrefPubMed
  • 13 Itokawa H, Saitou K, Morita H, Takeya K, Yamada K. Chem. Pharm. Bull. 1992; 40: 2984
    CrossrefPubMed
  • 14 Purser S, Moore PR, Swallow S, Gouverneur V. Chem. Soc. Rev. 2008; 37: 320
    CrossrefPubMed
  • 15 Wang J, Sánchez-Roselló M, Aceña JL, del Pozo C, Sorochinsky AE, Fustero S, Soloshonok VA, Liu H. Chem. Rev. 2014; 114: 2432
    CrossrefPubMed
  • 16 Johnson BM, Shu Y.-Z, Zhuo X, Meanwell NA. J. Med. Chem. 2020; 63: 6315
    CrossrefPubMed
  • 17 Van Heek M, France CF, Compton DS, McLeod RL, Yumibe NP, Alton KB, Sybertz EJ, Davies HR. Jr. J. Pharmacol. Exp. Ther. 1997; 283: 157
    CrossrefPubMed
  • 18 Clader JW. J. Med. Chem. 2004; 47: 1
    CrossrefPubMed
  • 19 Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn EG, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang AW, Isaakson PC. J. Med. Chem. 1997; 40: 1347
    CrossrefPubMed
  • 20 Hitotsuyanagi Y, Hirai M, Odagiri M, Komine M, Hasuda T, Fukaya H, Takeya K. Chem. Asian J. 2019; 14: 205
    CrossrefPubMed
  • 21 Hitotsuyanagi Y, Ishikawa H, Naito S, Takeya K. Tetrahedron Lett. 2003; 44: 5901
    CrossrefPubMed

      • For other syntheses of 14-membered cycloisodityrosines, see:
    • 22a Inaba T, Umezawa I, Yuasa M, Inoue T, Mihashi S, Itokawa H, Ogura K. J. Org. Chem. 1987; 52: 2957
      Crossref
    • 22b Boger DL, Yohannes D. J. Am. Chem. Soc. 1991; 113: 1427
      Crossref
    • 22c Boger DL, Patane MA, Zhou J. J. Am. Chem. Soc. 1994; 116: 8544
      Crossref
    • 22d Boger DL, Zhou J. J. Org. Chem. 1996; 61: 3938
      CrossrefPubMed
    • 22e Beugelmans R, Bigot A, Bois-Choussy M, Zhu J. J. Org. Chem. 1996; 61: 771
      CrossrefPubMed
    • 22f Bigot A, Dau M.-ET. H, Zhu J. J. Org. Chem. 1999; 64: 6283
      Crossref
    • 22g Cristau P, Martin M.-T, Dau M.-ET. H, Vors J.-P, Zhu J. Org. Lett. 2004; 6: 3183
      CrossrefPubMed
    • 22h Hitotsuyanagi Y. J. Nat. Med. 2021; 75: 752
      CrossrefPubMed
  • 23 12a and 12b To a solution of 9 (16.0 mg, 0.0299 mmol) in CH2Cl2 (30 mL) were added DMAP (43.9 mg, 0.359 mmol) and powdered 4 Å MS (200 mg), and the mixture was stirred at rt for 30 min. Cu(OAc)2 (65.2 mg, 0.359 mmol) was added and the resultant mixture was stirred at rt for 72 h. The mixture was then centrifuged and the supernatant was transferred to an InertSep PRS column (2 g/2 mL) and eluted with 1:1 EtOAc–CHCl3 (30 mL). The eluate was concentrated under reduced pressure, and the residue was separated by HPLC (H2O–MeOH, 50:50) to afford 12a and 12b as colorless amorphous solids. 12a Yield: 5.8 mg (40%); [α]D 25 –31.3 (c 0.41, MeOH). IR (film): 3312, 1764, 1710, 1664, 1518, 1501, 1260, 1166 cm–1. 1H NMR (500 MHz, CDCl3) δ = 1.46 (s, 9 H), 2.82 (overlapped, 1 H), 2.82 (dd, J = 16.5, 1.6 Hz, 1 H), 2.88 (dd, J = 16.5, 8.0 Hz, 1 H), 3.40 (dd, J = 13.2, 4.8 Hz, 1 H), 3.56 (s, 3 H), 3.92 (s, 3 H), 4.21 (m, 1 H), 4.41 (m, 1 H), 5.28 (br s, 1 H), 5.32 (br s, 1 H), 5.92 (br s, 1 H), 6.60 (dd, J = 8.2, 1.9 Hz, 1 H), 6.77 (d, J = 8.2 Hz, 1 H), 7.06–7.18 (m, 3 H). 13C NMR (125 MHz, CDCl3) δ = 28.2 (CH3, 3 C), 34.4 (CH2), 38.9 (CH2), 52.2 (CH3), 53.8 (CH), 56.2 (CH3), 57.3 (CH), 81.0 (C), 112.3 (CH), 114.8 (CH), 119.1 (CH), 122.6 (CH), 126.8 (CH), 127.1 (CH), 129.0 (C), 136.0 (C), 144.8 (C), 147.2 (C), 150.9 (C), 154.9 (C), 156.4 (CF), 170.4 (C), 170.6 (C). HR-ESI-MS: m/z [M + Na]+ calcd for C25H29FN2NaO7; 511.1856; found: 511.1857. 12b Yield: 2.4 mg (16%); [α]D 25 +38.7 (c 0.21, MeOH). IR (film): 3352, 1751, 1716, 1670, 1519, 1503, 1261, 1164 cm–1. 1H NMR (500 MHz, CDCl3) δ = 1.49 (s, 9 H), 2.76–2.90 (m, 3 H), 3.45 (dd, J = 13.4, 4.8 Hz, 1 H), 3.65 (s, 3 H), 3.94 (s, 3 H), 4.22 (m, 1 H), 4.58 (m, 1 H), 4.96 (d, J = 8.7 Hz, 1 H), 5.28 (s, 1 H), 6.03 (brd, J = 6.4 Hz, 1 H), 6.66 (dd, J = 8.2, 1.8 Hz, 1 H), 6.80 (d, J = 8.2 Hz, 1 H), 7.04 (d, J = 8.3 Hz, 1 H), 7.08 (d, J = 11.1 Hz, 1 H), 7.17 (t, J = 8.0 Hz, 1 H). 13C NMR (125 MHz, CDCl3) δ = 28.3 (CH3, 3 C), 34.8 (CH2), 38.5 (CH2), 52.4 (CH3), 53.9 (CH), 56.3 (CH3), 56.5 (CH), 81.4 (C), 112.3 (CH), 113.4 (CH), 120.5 (CH), 122.6 (CH), 124.6 (CH), 125.8 (CH), 130.0 (C), 135.9 (C), 144.9 (C), 147.1 (C), 150.7 (C), 154.7 (C), 156.7 (CF), 170.6 (C), 171.3 (C). HR-ESI-MS: m/z [M + Na]+ calcd for C25H29FN2NaO7; 511.1856; found: 511.1857.
  • 24 4a and 4b A LiOOH solution [LiOH·H2O (3.9 mg, 0.093 mmol) dissolved in 35% aq H2O2 (0.1 mL) and MeOH (0.2 mL)] was slowly added to a cooled (0 °C) solution of 15a (14.0 mg, 0.0152 mmol) in MeOH (0.1 mL), and the resulting mixture was stirred at 0 °C for 48 h. A 10% aq solution of citric acid (1 mL) and 5% aq NaHSO3 (0.5 mL) were added at 0 °C, and the resulting mixture was stirred for 15 min. The mixture was then extracted with EtOAc (3 × 1.5 mL), and the combined organic layers were washed with sat. aq NaCl (1 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. The residue was dissolved in CHCl3 (2 mL) and treated by slow addition of TFA (2 mL) at 0 °C, and the resultant solution was stirred at 0 °C for 30 min and then at rt for 2 h. Volatiles were removed under reduced pressure, and the residue was passed through a Bond Elut DEA column (500 mg/3 mL) using MeOH (30 mL) as the eluent. The eluate was concentrated to dryness under reduced pressure, and the residue was dissolved in DMF (12 mL). Et3N (21 μL, 0.15 mmol) and DPPA (6.5 μL, 0.030 mmol) were added at 0 °C, and the solution was stirred under argon at 0 °C for 4 d. The solvent was removed under reduced pressure, and the residue was dissolved in CHCl3 (4 mL). The solution was washed sequentially with sat. aq NaHCO3 (1 mL) and sat. aq NaCl (1 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. The residue was purified by HPLC (H2O–MeCN, 55:45) to give 4a as a colorless amorphous solid; yield: 3.7 mg (31%); [α]D 25 –213 (c 0.17, MeOH). IR (film): 3387, 1661, 1633, 1514 cm–1. 1H NMR (600 MHz, CDCl3) (major conformer): δ = 1.12 (d, J = 6.7 Hz, 3 H), 1.31 (d, J = 7.0 Hz, 3 H), 1.36 (d, J = 6.9 Hz, 3 H), 2.61 (dd, J = 11.4, 3.0 Hz, 1 H), 2.69 (s, 3 H), 2.85 (s, 3 H), 3.01 (dd, J = 17.8, 4.0 Hz, 1 H), 3.09 (dd, J = 17.8, 11.9 Hz, 1 H), 3.12 (s, 3 H), 3.36 (dd, J = 14.1, 10.9 Hz, 1 H), 3.39 (dd, J = 14.1, 4.8 Hz, 1 H), 3.58 (dd, J = 10.9, 4.8 Hz, 1 H), 3.65 (t, J = 11.4 Hz, 1 H), 3.79 (s, 3 H), 3.95 (s, 3 H), 4.35 (quintet, J = 6.9 Hz, 1 H), 4.58 (dd, J = 11.9, 4.0 Hz, 1 H), 4.61 (d, J = 1.8 Hz, 1 H), 4.75 (dq, J = 7.7, 6.7 Hz, 1 H), 4.85 (dq, J = 8.5, 6.9 Hz, 1 H), 5.41 (dd, J = 11.4, 3.0 Hz, 1 H), 6.05 (d, J = 8.5 Hz, 1 H), 6.41 (d, J = 6.7 Hz, 1 H), 6.65 (dd, J = 8.3, 1.8 Hz, 1 H), 6.69 (d, J = 7.7 Hz, 1 H), 6.837 (app d, J = 8.6 Hz, 2 H), 6.843 (d, J = 8.3 Hz, 1 H), 7.05 (app d, J = 8.6 Hz, 2 H), 7.06 (dd, J = 11.2, 2.0 Hz, 1 H), 7.18 (dd, J = 8.4, 2.0 Hz, 1 H), 7.28 (t, J = 8.2 Hz, 1 H). 13C NMR (150 MHz, CDCl3) (major conformer): δ = 16.7 (CH3), 18.5 (CH3), 20.7 (CH3), 29.4 (CH3), 30.5 (CH3), 32.7 (CH2), 35.8 (CH2), 37.0 (CH2), 39.7 (CH3), 44.6 (CH), 46.4 (CH), 47.9 (CH), 54.1 (CH), 55.3 (CH3), 56.4 (CH3), 57.4 (CH), 68.4 (CH), 112.3 (CH), 113.0 (CH), 114.1 (CH, 2C), 120.6 (CH), 122.0 (CH), 125.9 (CH), 127.8 (CH), 128.1 (C), 130.3 (CH, 2C), 130.7 (C), 137.6 (C), 145.1 (C), 147.1 (C), 151.8 (C), 156.1 (C), 158.4 (C), 168.0 (C), 169.4 (C), 170.6 (C), 171.8 (C), 172.2 (C), 172.4 (C). 19F NMR (471 MHz, CDCl3) (major conformer): δ = –129.8 (dd, J = 11.2, 8.0 Hz). HR-ESI-MS: m/z [M + H]+ calcd for C41H50FN6O9: 789.3623; found: 789.3621. 4b Prepared from 15b (9.6 mg, 0.0104 mmol) by using the same procedure as that described for the synthesis of 4a as a colorless amorphous solid; yield: 2.4 mg (29%); [α]D 25 –203 (c 0.12, MeOH). IR (film): 3387, 1666, 1633, 1514 cm–1. 1H NMR (600 MHz, CDCl3) (major conformer): δ = 1.13 (d, J = 6.7 Hz, 3 H), 1.32 (d, J = 6.9 Hz, 3 H), 1.36 (d, J = 6.9 Hz, 3 H), 2.61 (dd, J = 11.4, 3.2 Hz, 1 H), 2.71 (s, 3 H), 2.86 (s, 3 H), 2.99 (dd, J = 18.2, 3.6 Hz, 1 H), 3.12 (s, 3 H), 3.15 (dd, J = 18.2, 12.1 Hz, 1 H), 3.36 (dd, J = 14.0, 10.9 Hz, 1 H), 3.39 (dd, J = 14.0, 4.9 Hz, 1 H), 3.58 (dd, J = 10.9, 4.9 Hz, 1 H), 3.66 (t, J = 11.4 Hz, 1 H), 3.79 (s, 3 H), 3.94 (s, 3 H), 4.35 (quintet, J = 6.8 Hz, 1 H), 4.56 (d, J = 2.0 Hz, 1 H), 4.59 (dd, J = 12.1, 3.6 Hz, 1 H), 4.74 (dq, J = 7.7, 6.7 Hz, 1 H), 4.87 (dq, J = 8.5, 6.9 Hz, 1 H), 5.49 (dd, J = 11.4, 3.2 Hz, 1 H), 6.02 (d, J = 8.5 Hz, 1 H), 6.44 (d, J = 6.6 Hz, 1 H), 6.64 (dd, J = 8.3, 2.0 Hz, 1 H), 6.69 (d, J = 7.7 Hz, 1 H), 6.84 (app. d, J = 8.6 Hz, 2 H), 6.84 (overlapped, 1 H), 6.95 (t, J = 8.1 Hz, 1 H), 7.05 (app. d, J = 8.6 Hz, 2 H), 7.06 (dd, J = 8.1, 1.8 Hz, 1 H), 7.24 (dd, J = 11.7, 1.8 Hz, 1 H). 13C NMR (150 MHz, CDCl3) (major conformer): δ = 16.7 (CH3), 18.5 (CH3), 20.7 (CH3), 29.3 (CH3), 30.5 (CH3), 32.7 (CH2), 35.4 (CH2), 37.0 (CH2), 39.8 (CH3), 44.6 (CH), 46.4 (CH), 47.9 (CH), 54.0 (CH), 55.3 (CH3), 56.3 (CH3), 57.6 (CH), 68.4 (CH), 111.8 (CH), 112.7 (CH), 114.1 (CH, 2C), 118.8 (CH), 121.8 (CH), 126.4 (CH), 128.1 (CH), 128.6 (C), 130.3 (CH, 2C), 130.7 (C), 137.2 (C), 144.7 (C), 146.7 (C), 151.8 (C), 158.0 (C), 158.4 (C), 168.0 (C), 169.2 (C), 170.5 (C), 171.9 (C), 172.1 (C), 172.4 (C). 19F NMR (471 MHz, CDCl3) (major conformer): δ = –132.9 (t, J = 9.2 Hz). HR-ESI-MS: m/z [M + H]+ calcd for C41H50FN6O9: 789.3623; found: 789.3618.
  • 25 Morita H, Kondo K, Hitotsuyanagi Y, Takeya K, Itokawa H, Tomioka N, Itai A, Iitaka Y. Tetrahedron 1991; 47: 2757
    CrossrefPubMed